Barw Barw Medical Journal 2960-1959 2024 03 02 Post COVID-19 Pulmonary Fibrosis Management: A Systematic Review 10.58742/cgrahg12 eng Hamdi Yahya Al Turkey Faculty of Medicine, Taiz University, Taiz City, Yemen. Hamdi.Turkey@gmail.com Aland S. Abdullah College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. alandsalihh@gmail.com Harem K. Ahmed Shar Teaching Hospital, Sulaymaniyah, Kurdistan, Iraq. harem.kareem@gmail.com Bnar J. Hama Amin Shar Teaching Hospital, Sulaymaniyah, Kurdistan, Iraq. bnar.hamaamin@gmail.com Yousif M. Mahmood Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. yousuf.smarthealth@gmail.com Suhaib H. Kakamad Department of Immunology and Hematology, College of Medicine, Kurdistan University of Medical Science, Sanandaj, Iran. suhaib.kakamad@gmail.com Aso N. Qadir Smart Health Tower/Raparin, Rania, Sulaymaniyah, Kurdistan, Iraq. aso.qadir@gmail.com Hemin S. Mohammed Kalar General Hospital, Kalar, Sulaymaniyah, Kurdistan, Iraq. hemn.ali@gmail.com Hemn H. Bayz Smart Health Tower/Raparin, Rania, Sulaymaniyah, Kurdistan, Iraq. hemn.bayz@gmail.com Shevan M. Mustafa Kscien Organization for Scientific Research (Middle East office), Hamid Street, Azadi Mall, Sulaymaniyah, Kurdistan, Iraq. shevan.mustafa@gmail.com Sanaa O. Karim College of Nursing, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. sanaa.karim@gmail.com Hawbash M. Rahim Medical Laboratory Science Department, College of Health Sciences, University of Human Development, Sulaymaniyah, Kurdistan Region, Iraq. hawbash.mhamad96@gmail.com Berun A. Abdalla Department of Biology, College of Education, University of Sulaimani, Sulaymaniyah, Kurdistan, Iraq. berun.anwer95@gmail.com Fahmi H. Kakamad College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. fahmi.hussein@univsul.edu.iq 2024 01 20 Introduction Post-COVID-19 Pulmonary Fibrosis (PC-19-PF) is among the complications following COVID-19. It is the complication that is associated with the most amount of long-term impact on the respiratory system. Different physicians approach management in different ways; therefore, we conduct a study to neatly summarize all the different management and their possible outcomes. Methods The databases that were searched included CINAHL, PubMed/MEDLINE, Cochrane Library, Web of Science, and EMBASE to identify English language studies published up to October 5th, 2023. Results Initially, the systematic search conducted brought 150 papers. Out of the 150, 13 of them were included in this study. A total of 662 patients were included in the study, all with different managements for COVID-19-induced pulmonary fibrosis. The mean age was 61.8 years. Many comorbidities were observed in patients with COVID-19-induced pulmonary fibrosis. Different treatment regimens were picked based on the different conditions of the patients but as far as antifibrotics go, Pirfenidone and Nintedanib were the most commonly used ones. Conclusion Both antifibrotics and steroids seemed to yield justifiable outcomes when used separately as well as when used in combination.